Addressing and Overcoming Disparities in GVHD

Overview

Journal Blood Adv

Specialty Hematology

Date 2024 Sep 24

PMID 39316390

Authors

Hemant S Murthy

Affiliations

Soon will be listed here.

References

Knight J, Rizzo J, Logan B, Wang T, Arevalo J, Ma J . Low Socioeconomic Status, Adverse Gene Expression Profiles, and Clinical Outcomes in Hematopoietic Stem Cell Transplant Recipients. Clin Cancer Res. 2015; 22(1):69-78. PMC: 4703514. DOI: 10.1158/1078-0432.CCR-15-1344. View

Chang E, Iukuridze A, Echevarria M, Teh J, Chanson D, Ky B . Feasibility and Acceptability of Using a Telehealth Platform to Monitor Cardiovascular Risk Factors in Hematopoietic Cell Transplantation Survivors at Risk for Cardiovascular Disease. Biol Blood Marrow Transplant. 2020; 26(6):1233-1237. DOI: 10.1016/j.bbmt.2020.02.027. View

Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R . Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. N Engl J Med. 2020; 382(19):1800-1810. DOI: 10.1056/NEJMoa1917635. View

Miklos D, Cutler C, Arora M, Waller E, Jagasia M, Pusic I . Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017; 130(21):2243-2250. PMC: 6033048. DOI: 10.1182/blood-2017-07-793786. View

Auletta J, Sandmaier B, Jensen E, Majhail N, Knutson J, Nemecek E . The ASTCT-NMDP ACCESS Initiative: A Collaboration to Address and Sustain Equal Outcomes for All across the Hematopoietic Cell Transplantation and Cellular Therapy Ecosystem. Transplant Cell Ther. 2022; 28(12):802-809. DOI: 10.1016/j.jtct.2022.09.020. View

Phelan R, Chen M, Bupp C, Bolon Y, Broglie L, Brunner-Grady J . Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. Transplant Cell Ther. 2022; 28(7):409.e1-409.e10. PMC: 9840526. DOI: 10.1016/j.jtct.2022.04.012. View

Shaw B, Jimenez-Jimenez A, Burns L, Logan B, Khimani F, Shaffer B . Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial. Transplant Cell Ther. 2022; 29(3):208.e1-208.e6. PMC: 9992261. DOI: 10.1016/j.jtct.2022.12.017. View

Lee K, Shamunee J, Lindenfeld L, Ross E, Hageman L, Sedrak M . Feasibility of implementing a supervised telehealth exercise intervention in frail survivors of hematopoietic cell transplantation: a pilot randomized trial. BMC Cancer. 2023; 23(1):390. PMC: 10150529. DOI: 10.1186/s12885-023-10884-5. View

Majhail N, Nayyar S, Santibanez M, Murphy E, Denzen E . Racial disparities in hematopoietic cell transplantation in the United States. Bone Marrow Transplant. 2011; 47(11):1385-90. PMC: 3848311. DOI: 10.1038/bmt.2011.214. View

10.

Farhadfar N, Rashid N, Chen K, DeVos J, Wang T, Ballen K . Racial, ethnic, and socioeconomic diversity and outcomes of patients with graft-versus-host disease: a CIBMTR analysis. Blood Adv. 2024; 8(18):4963-4976. PMC: 11496972. DOI: 10.1182/bloodadvances.2024013074. View

11.

Zeiser R, Polverelli N, Ram R, Hashmi S, Chakraverty R, Middeke J . Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. N Engl J Med. 2021; 385(3):228-238. DOI: 10.1056/NEJMoa2033122. View

12.

Auletta J, Kou J, Chen M, Bolon Y, Broglie L, Bupp C . Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Transplant Cell Ther. 2023; 29(6):346.e1-346.e10. PMC: 10239334. DOI: 10.1016/j.jtct.2023.03.007. View

13.

Cutler C, Lee S, Arai S, Rotta M, Zoghi B, Lazaryan A . Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021; 138(22):2278-2289. PMC: 8641099. DOI: 10.1182/blood.2021012021. View

14.

Waller E, Miklos D, Cutler C, Arora M, Jagasia M, Pusic I . Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. Biol Blood Marrow Transplant. 2019; 25(10):2002-2007. DOI: 10.1016/j.bbmt.2019.06.023. View

15.

Bolanos-Meade J, Hamadani M, Wu J, Al Malki M, Martens M, Runaas L . Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. N Engl J Med. 2023; 388(25):2338-2348. PMC: 10575613. DOI: 10.1056/NEJMoa2215943. View